0.45Open0.45Pre Close0 Volume51 Open Interest19.00Strike Price0.00Turnover8412.33%IV10.26%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier-2DDays to Expiry0.45Extrinsic Value100Contract SizeAmericanOptions Type0.3178Delta0.1524Gamma39.20Leverage Ratio-470.7078Theta0.0000Rho12.46Eff Leverage0.0001Vega
MediWound Stock Discussion
MediWound to Host Virtual Key Opinion Leader Event to Discuss EscharEx® Phase III VALUE Study in Venous Leg Ulcers and Its Commercial Opportunity on January 8, 2025
Tuesday, 17th December at 8:00 am
YAVNE, Israel, Dec. 17, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced it will host a virtual Key Opinion Leader (KOL) event on Wednesday, January 8, 2025, at 10:00 AM ET. T...
·3 mins ago
Mediwound Announces U.S. Food and Drug Administration Approval of Nexobrid® for the Treatment of Pediatric Patients With Severe Thermal Burns
No comment yet